Back to Search Start Over

Methotrexate and immunogenicity of vaccines in patients with rheumatic diseases

Authors :
В. S. Belov
N. V. Muravyeva
Е. L. Nasonov
Source :
Научно-практическая ревматология, Vol 62, Iss 2, Pp 192-202 (2024)
Publication Year :
2024
Publisher :
IMA PRESS LLC, 2024.

Abstract

Currently, methotrexate (MT) remains one of the immunosuppressive drugs most commonly used in rheumatology. However, its effect on the immunogenicity of vaccines has until recently been studied only to a limited extent, which has led to the lack of clear recommendations for the use of MT during vaccination. Significant progress was made during the COVID-19 pandemic due to the dynamic development of vaccine research, including in patients with immuno-inflammatory rheumatic diseases. The review presents data on the effect of MT on the immunogenicity of vaccines against influenza, pneumococcus, herpes zoster, tetanus/diphtheria/pertussis, yellow fever and COVID-19 (including humoral and cellular responses) in rheumatological patients. The necessity of observing certain time intervals during vaccination in the case of MT use has been demonstrated. The potential mechanisms by which MT influences the immunogenicity of vaccines are presented. The importance of further clinical studies is emphasized in order to assess the effect of MT therapy on the vaccine response and to develop methods for its optimization.

Details

Language :
Russian
ISSN :
19954484 and 19954492
Volume :
62
Issue :
2
Database :
Directory of Open Access Journals
Journal :
Научно-практическая ревматология
Publication Type :
Academic Journal
Accession number :
edsdoj.6f9c22d60bd74a92a54c79f4015d1a88
Document Type :
article
Full Text :
https://doi.org/10.47360/1995-4484-2024-192-202